TITaeko Ishii

Taeko Ishii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Taeko Ishii has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Spontaneous perirenal hematoma due to Wegener’s granulomatosis after initiation of immunosuppressant

    by Taeko Ishii, Yoshinori Katada, Yukihiko Saeki

    Spontaneous perirenal hematoma (SPH) is a rare, life-threatening condition. We present a patient with Wegener’s granulomatosis (WG) who developed SPH soon after the initiation of immunosuppressant therapy. Few cases of SPH as a complication of WG have been reported, though a rupture of an aneurysm in patients with polyarteritis nodosa can lead to SPH. Though immunosuppressant therapy is considered to be the first-line therapy for SPH with vasculitis, SPH could still occur after the initiation of an adequate treatment regimen.


    • 1 November 2008
      • Vol. 57  (11) , 1155-65

    [Clinical pathway for management of patients with acute asthma attack].

    by Naoto Azuma, Yoshinori Katada, Masaaki Kobayashi, Makiko Kojima, Yumi Nakajima, Miyo Shibano, Hitomi Tomita, Takao Yamanaka, Yoshinori Harada, Taeko Ishii, et al.

    There have been few reports of clinical pathway (CP) for treatment of asthma attack, because patients with asthma always admit emergently and the severity varies. We introduced CP so that standard asthma treatment can be widely used, and investigated its clinical usefulness. We designed a new CP for treating asthma attack according to the guideline (Japanese guideline (JGL) and Global Initiative for Asthma (GINA)). 136 patients who admitted to our hospital due to asthma attack from January 1999 to November 2006, were enrolled our study. Excluding cases complicated with pneumonia, COPD or cardiac failure, we evaluated 46 cases treated with the CP comparing with 19 cases treated without the CP. The clinical evaluations include systemic and inhaled steroid use, FEV1.0%, history of asthma, and the duration of asthma attack. Furthermore, we investigated difference between cases with and without prolonged admission. While the rates of systemic and inhaled steroid use in cases without the CP were 57.9% and 52.6% respectively, those in cases with the CP were approximately 100%. Employing the CP, FEV 1.0% at discharge time was elevated from 71.7% to 76.3% and the duration of hospitalization was shortened from 14.2 days to 11.5 days. Mean age of the cases with prolonged admission was higher than the rest. The asthma CP is an effective way for the standard treatment according to the guideline to be used widely even by doctors who are not familiar with asthma treatment. It improves the efficacy of in-hospital treatment.

    • 1 October 2002
      • Vol. 29  (10) , 2061-7

    Enhanced local production of osteopontin in rheumatoid joints.

    by Shiro Ohshima, Norihiko Yamaguchi, Katsuhiro Nishioka, Toru Mima, Taeko Ishii, Mitsuko Umeshita-Sasai, Hideyuki Kobayashi, Masatoshi Shimizu, Yoshinori Katada, Shigeyuki Wakitani, et al.

    To investigate the involvement of osteopontin (OPN) in the pathogenesis of rheumatoid arthritis (RA), localization and production of OPN were examined in patients with RA. Localization of OPN in the rheumatoid synovium was examined by immunohistochemistry. In vitro OPN production by cultured synovial cells from patients with RA (n = 5) and with osteoarthritis (OA) (n = 5) was assessed by ELISA. OPN concentrations in plasma and synovium were quantified in patients with RA (n = 23) by 2 distinct ELISA systems to measure both thrombin cleaved and non-cleaved OPN. The same experiments were done in patients with OA (n = 15) and healthy volunteers (n = 10) as a control. OPN was highly detected by immunohistochemistry predominantly in the RA synovial lining cells, while less and scattered OPN was detected in OA synovial tissues. ELISA revealed that cultured RA synovial cells secreted significantly more OPN than OA cells. ELISA also showed a marked increase of OPN levels in synovial fluid (SF) of patients with RA and with OA compared to the control plasma OPN levels, although OPN levels were not increased in RA and OA plasma compared to healthy controls. SF OPN levels of patients with RA were significantly higher than those of patients with OA, and correlated with serum C-reactive protein levels. The ratios of thrombin cleaved versus non-cleaved OPN were significantly increased in RA plasma and SF compared with OA plasma and SF and plasma from healthy controls. Our results revealed enhanced local production of OPN in rheumatoid joints, suggesting involvement of OPN in the pathogenesis of RA.


    • 1 June 2002
      • Vol. 29  (6) , 1176-82

    Antigen induced arthritis (AIA) can be transferred by bone marrow transplantation: evidence that interleukin 6 is essential for induction of AIA.

    by Hideyuki Kobayashi, Shiro Ohshima, Katsuhiro Nishioka, Norihiko Yamaguchi, Mitsuko Umeshita-Sasai, Taeko Ishii, Toru Mima, Tadamitsu Kishimoto, Ichiro Kawase, Yukihiko Saeki

    To investigate the role of bone marrow cells (BMC) in the induction of antigen induced arthritis (AIA), the expression of 3 major proinflammatory cytokines, interleukin 1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and IL-6, was examined in the bone marrow (BM) of mice with AIA. We also examined whether AIA could be transferred by bone marrow transplantation (BMT). Expression of IL-1beta, TNF-alpha, and IL-6 in BMC was assessed by immunohistochemistry throughout the course of AIA. BMT experiments were performed using 2 different mouse genotypes, wild type (IL-6+/+) and IL-6 deficient (IL-6-/-) mice, as a donor. The gradation of AIA was evaluated histologically. IL-6 was highly expressed in the BM at induction as well as during progression of AIA, while TNF-alpha showed a marginal expression, and no significant expression of IL-1beta was detected throughout the course of AIA. In BMT experiments, all irradiated IL-6+/+ mice developed typical AIA by transplantation of BMC from immunized IL-6+/+ mice, whereas almost no irradiated IL- 6+/+ mice transplanted with BMC from the immunized IL-6-/- mice developed definite arthritis. These results suggest that BMC play a critical role and IL-6 is a key cytokine for the induction and progression of AIA. There may be clinical benefits in the blockade of IL-6 and BMT in the treatment of rheumatoid arthritis.


    • 1 March 2002
      • Vol. 60  (3) , 551-5

    [Monoclonal antibody therapy for rheumatoid arthritis].

    by Taeko Ishii, Yukihiko Saeki

    Rheumatoid arthritis(RA) is a systemic chronic inflammatory disease characterized by destructive polyarthritis. Although its etiology and pathogenesis are still to be elucidated, recent cumulative evidence has suggested both T cells and proinflammatory cytokines (such as tumor necrosis factor(TNF)-alpha, interleukin(IL)-1, IL-6) play pivotal roles in the pathogenesis. Therefore, they are thought to be optimal therapeutic targets. In fact, new therapies targeted to T cells and proinflammatory cytokines using biological agents including monoclonal antibodies have been developed extensively. Among them, anti-proinflammatory cytokine therapies, such as anti-TNF-alpha therapy, have shown an excellent efficacy and some are currently accepted as a new promising therapy for RA. It is expected that further investigation will provide additional insights into cure of RA.